OncoMatch/Clinical Trials/NCT06838910
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
Is NCT06838910 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Experimental: tislelizumab+anlotinib for thymic carcinoma.
Treatment: Experimental: tislelizumab+anlotinib — It is an open-lable, single-arm, single-center, phase II clinical trial conducted in China, and plan to recruiting 20 patients who were progressed after first line chemotherapy or chemotherapy combined with immunotherapy. The purpose of this study is to evaluate the safety and efficacy of tislelizumab combined with anlotinib as second-line in thymoma and thymic carcinoma.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy — first-line
Disease progression during or after first-line chemotherapy (with or without immunotherapy)
Cannot have received: anti-angiogenesis drug (anlotinib)
Prior treatment with anlotinib or any other anti-angiogenesis drugs
Lab requirements
Blood counts
neutrophil count (ANC) ≥ 1.5×10^9/L; platelet count (PLT) ≥100 × 10^9/L; hemoglobin (Hb) ≥80g/L
Liver function
total bilirubin (TBIL) ≤ 1.5× ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5× ULN, serum albumin (ALB) ≥28g/L
Cardiac function
left ventricular ejection fraction (LVEF) ≥50%
Vital organ function meets the following criteria: Hematological examination...; total bilirubin (TBIL) ≤ 1.5× ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5× ULN, serum albumin (ALB) ≥28g/L; left ventricular ejection fraction (LVEF) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify